Literature DB >> 17566038

Double resistance to imatinib and AMG 706 caused by multiple acquired KIT exon 17 mutations in a gastrointestinal stromal tumour.

Florian Grabellus, Peter Ebeling, Karl Worm, Sien-Yi Sheu, Gerald Antoch, Andrea Frilling, Kurt W Schmid.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17566038      PMCID： PMC1994367          DOI： 10.1136/gut.2006.115923

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


× No keyword cloud information.
  8 in total

1.  Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate.

Authors:  Hans Prenen; Jan Cools; Nicole Mentens; Cedric Folens; Raf Sciot; Patrick Schöffski; Allan Van Oosterom; Peter Marynen; Maria Debiec-Rychter
Journal:  Clin Cancer Res       Date:  2006-04-15       Impact factor: 12.531

2.  Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies.

Authors:  Marcus M Schittenhelm; Sharon Shiraga; Arin Schroeder; Amie S Corbin; Diana Griffith; Francis Y Lee; Carsten Bokemeyer; Michael W N Deininger; Brian J Druker; Michael C Heinrich
Journal:  Cancer Res       Date:  2006-01-01       Impact factor: 12.701

3.  Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations.

Authors:  Eva Wardelmann; Nadja Thomas; Sabine Merkelbach-Bruse; Katharina Pauls; Nicola Speidel; Reinhard Büttner; Heiner Bihl; Claudia C Leutner; Thomas Heinicke; Peter Hohenberger
Journal:  Lancet Oncol       Date:  2005-04       Impact factor: 41.316

4.  Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal.

Authors:  L G Kindblom; H E Remotti; F Aldenborg; J M Meis-Kindblom
Journal:  Am J Pathol       Date:  1998-05       Impact factor: 4.307

5.  Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation.

Authors:  Cristina R Antonescu; Peter Besmer; Tianhua Guo; Knarik Arkun; Glory Hom; Beata Koryotowski; Margaret A Leversha; Philip D Jeffrey; Diann Desantis; Samuel Singer; Murray F Brennan; Robert G Maki; Ronald P DeMatteo
Journal:  Clin Cancer Res       Date:  2005-06-01       Impact factor: 12.531

6.  Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.

Authors:  S Hirota; K Isozaki; Y Moriyama; K Hashimoto; T Nishida; S Ishiguro; K Kawano; M Hanada; A Kurata; M Takeda; G Muhammad Tunio; Y Matsuzawa; Y Kanakura; Y Shinomura; Y Kitamura
Journal:  Science       Date:  1998-01-23       Impact factor: 47.728

7.  Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate.

Authors:  Eva Wardelmann; Sabine Merkelbach-Bruse; Katharina Pauls; Nadja Thomas; Hans-Ulrich Schildhaus; Thomas Heinicke; Nicola Speidel; Torsten Pietsch; Reinhard Buettner; Daniel Pink; Peter Reichardt; Peter Hohenberger
Journal:  Clin Cancer Res       Date:  2006-03-15       Impact factor: 12.531

8.  Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.

Authors:  Michael C Heinrich; Christopher L Corless; George D Demetri; Charles D Blanke; Margaret von Mehren; Heikki Joensuu; Laura S McGreevey; Chang-Jie Chen; Annick D Van den Abbeele; Brian J Druker; Beate Kiese; Burton Eisenberg; Peter J Roberts; Samuel Singer; Christopher D M Fletcher; Sandra Silberman; Sasa Dimitrijevic; Jonathan A Fletcher
Journal:  J Clin Oncol       Date:  2003-12-01       Impact factor: 44.544
  8 in total
  5 in total

Review 1.  Targeted therapy in GIST: in silico modeling for prediction of resistance.

Authors:  Marco A Pierotti; Elena Tamborini; Tiziana Negri; Sabrina Pricl; Silvana Pilotti
Journal:  Nat Rev Clin Oncol       Date:  2011-03       Impact factor: 66.675

2.  A Phase I clinical trial of the combination of imatinib and paclitaxel in patients with advanced or metastatic solid tumors refractory to standard therapy.

Authors:  Michael J Pishvaian; Rebecca Slack; Eunice Y Koh; Jan H Beumer; Marion L Hartley; Ion Cotarla; John Deeken; Aiwu Ruth He; Jimmy Hwang; Shakun Malik; Kashif Firozvi; Minetta Liu; Beth Elston; Sandy Strychor; Merrill J Egorin; John L Marshall
Journal:  Cancer Chemother Pharmacol       Date:  2012-09-27       Impact factor: 3.333

3.  Impact of KIT and PDGFRA gene mutations on prognosis of patients with gastrointestinal stromal tumors after complete primary tumor resection.

Authors:  Ying-Yong Hou; Florian Grabellus; Frank Weber; Yang Zhou; Yun-Shan Tan; Jun Li; Kun-Tang Shen; Jin Qin; Yi-Hong Sun; Xin-Yu Qin; Maximillian Bockhorn; Guido Gerken; Christoph E Broelsch; Andrea Frilling
Journal:  J Gastrointest Surg       Date:  2009-03-17       Impact factor: 3.452

Review 4.  Novel approaches to gastrointestinal stromal tumors resistant to imatinib and sunitinib.

Authors:  Philippe A Cassier; Armelle Dufresne; Samia Arifi; Hiba El Sayadi; Isabelle Ray-Coquard; Pierre-Paul Bringuier; Jean-Yves Scoazec; Laurent Alberti; Jean-Yves Blay
Journal:  Curr Gastroenterol Rep       Date:  2008-12

5.  An alternative high output tissue microarray technique.

Authors:  Yuan Shi; Deming He; Yingyong Hou; Qin Hu; Chen Xu; Yalan Liu; Dongxian Jiang; Jieakesu Su; Haiying Zeng; Yunshan Tan
Journal:  Diagn Pathol       Date:  2013-01-21       Impact factor: 2.644
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.